PDUFA Date For Rilonacept (IL-1 Trap) Extended Three Months By FDA
Nov 7th 2007Drug InformationPharma Industry
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that it received notification earlier in the day from the United States Food and Drug Administration (FDA) that the action date for FDA’s priority review of the Biologics License Application (BLA) for rilonacept (IL-1 Trap) for the long-term treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) has been extended to February 29, 2008. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
